Zhang Jing, Zamani Mostafa, Thiele Christoph, Taher Jennifer, Amir Alipour Mohsen, Yao Zemin, Adeli Khosrow
From the Molecular Structure and Function Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada (J.Z., M.Z., J.T., K.A.); Department of Biochemistry (M.Z., K.A.) and Department of Laboratory Medicine and Pathobiology (J.T., K.A.), University of Toronto, Ontario, Canada; Biochemistry and Cell Biology of Lipids Unit, LIMES Institute, University of Bonn, Germany (C.T.); and Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada (M.A.A., Z.Y.).
Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):633-642. doi: 10.1161/ATVBAHA.117.309000. Epub 2017 Feb 9.
AUP1 (ancient ubiquitous protein 1) is an endoplasmic reticulum-associated protein that also localizes to the surface of lipid droplets (LDs), with dual role in protein quality control and LD regulation. Here, we investigated the role of AUP1 in hepatic lipid mobilization and demonstrate critical roles in intracellular biogenesis of apoB100 (apolipoprotein B-100), LD mobilization, and very-low-density lipoprotein (VLDL) assembly and secretion. APPROACH AND RESULTS: siRNA (short/small interfering RNA) knockdown of AUP1 significantly increased secretion of VLDL-sized apoB100-containing particles from HepG2 cells, correcting a key metabolic defect in these cells that normally do not secrete much VLDL. Secreted particles contained higher levels of metabolically labeled triglyceride, and AUP1-deficient cells displayed a larger average size of LDs, suggesting a role for AUP1 in lipid mobilization. Importantly, AUP1 was also found to directly interact with apoB100, and this interaction was enhanced with proteasomal inhibition. Knockdown of AUP1 reduced apoB100 ubiquitination, decreased intracellular degradation of newly synthesized apoB100, and enhanced extracellular apoB100 secretion. Interestingly, the stimulatory effect of AUP1 knockdown on VLDL assembly was reminiscent of the effect previously observed after MEK-ERK (mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) inhibition; however, further studies indicated that the AUP1 effect was independent of MEK-ERK signaling.
In summary, our findings reveal an important role for AUP1 as a regulator of apoB100 stability, hepatic LD metabolism, and intracellular lipidation of VLDL particles. AUP1 may be a crucial factor in apoB100 quality control, determining the rate at which apoB100 is degraded or lipidated to enable VLDL particle assembly and secretion.
AUP1(古老泛在蛋白1)是一种内质网相关蛋白,也定位于脂滴(LD)表面,在蛋白质质量控制和LD调节中具有双重作用。在此,我们研究了AUP1在肝脏脂质动员中的作用,并证明其在载脂蛋白B100(apoB100)的细胞内生物合成、LD动员以及极低密度脂蛋白(VLDL)组装和分泌中起关键作用。
通过小干扰RNA(siRNA)敲低AUP1可显著增加HepG2细胞中分泌的VLDL大小的含apoB100颗粒,纠正了这些通常不分泌大量VLDL的细胞中的关键代谢缺陷。分泌的颗粒含有更高水平的代谢标记甘油三酯,且AUP1缺陷细胞显示出更大的平均LD大小,表明AUP1在脂质动员中起作用。重要的是,还发现AUP1直接与apoB100相互作用,并且这种相互作用在蛋白酶体抑制时增强。敲低AUP1可减少apoB100泛素化,降低新合成的apoB100的细胞内降解,并增强细胞外apoB100分泌。有趣的是,敲低AUP1对VLDL组装的刺激作用让人想起先前在抑制丝裂原活化蛋白激酶激酶-细胞外信号调节激酶(MEK-ERK)后观察到的效应;然而,进一步研究表明AUP1的作用独立于MEK-ERK信号传导。
总之,我们的研究结果揭示了AUP1作为apoB100稳定性、肝脏LD代谢以及VLDL颗粒细胞内脂质化调节剂的重要作用。AUP1可能是apoB100质量控制中的关键因素,决定了apoB100被降解或脂质化以实现VLDL颗粒组装和分泌的速率。